GTAC@MGI supports industry led clinical trials that rely on consistent, well documented genomic and multi omic data from difficult samples.
We position molecular assays where they matter most so constrained clinical material can still support clear translational readouts.
Assays chosen with FFPE age, input limits, and tumor content in mind.
Baseline and on treatment sampling that can work with small biopsies.
Run level controls and documented thresholds for which samples can be used.
Pathway and signature level analyses that link molecular data to trial endpoints.
Groups come to GTAC@MGI when sample quality, assay design, and data interpretation all have to work on the first attempt.
We routinely work with material that would not meet standard discovery study criteria.
These trials show how sequencing and expression data from difficult samples can still drive translational endpoints.
Exome and RNA seq from paired biopsies in ER positive and HER2 positive disease supported PAM50 subtype calls, Ki67 assessment, and pathway analyses that informed trial readouts.
Read publicationRNA seq from archived FFPE tumors in advanced squamous non small cell lung cancer supported a gene expression signature used for biomarker driven subgroup analysis.
Read publicationMGI also supports discovery and translational programs that surround trial activity, including assay development, pilot work, and large cohort studies.
